Advertisement

 

 

Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco.

Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco.
Author Information (click to view)

Haban H, Benchekroun S, Sadeq M, Benjouad A, Amzazi S, Oumzil H, Elharti E,


Haban H, Benchekroun S, Sadeq M, Benjouad A, Amzazi S, Oumzil H, Elharti E, (click to view)

Haban H, Benchekroun S, Sadeq M, Benjouad A, Amzazi S, Oumzil H, Elharti E,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

BMC public health 2017 09 2917(1) 752 doi 10.1186/s12889-017-4776-8

Abstract
BACKGROUND
Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country.

METHODS
Forty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups.

RESULTS
The median age was 51 ± 35 months for the HIV group and 50 ± 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs ≥10mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response. CONCLUSION
In this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children.

Submit a Comment

Your email address will not be published. Required fields are marked *

one × three =

[ HIDE/SHOW ]